Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Correcting to show CEO was referring to vaccine production not efficacy in headline, first and 4th paragraphs)* To double supplies to 200 mln a month by April* To report U.S. trial results by end March* Forecasts 2021 core EPS of $4.75 to $5.00* Q4...
Read more* To double supplies to 200 mln a month by April* To report U.S. trial results by end March* Forecasts 2021 core EPS of $4.75 to $5.00* Q4 sales beat expectations, profit in line* African Union says will use shot in countries without SA variant (Ad...
Read more* To double supplies to 200 mln a month by April* To report U.S. trial results by end March* Forecasts 2021 core EPS of $4.75 to $5.00* Q4 sales beat expectations, profit in line* African Union to use shot in countries without SA variant (Adds quota...
Read more* To double supplies to 200 mln a month by April* To report U.S. trial results by end March* Forecasts 2021 core EPS of $4.75 to $5.00* Q4 sales beat expectations, profit in line* African Union to use shot in countries without SA variant (Adds quota...
Read more
(Sharecast News) - A top UK health official expressed concern about the likely spread of the so-called UK variant worldwide and the fact that it was continuing to mutate.
Read more(Sharecast News) - The African Union's disease control body said on Thursday that it would continue using the AstraZeneca Covid19 vaccine, after trial data showed it had greatly reduced efficacy against the coronavirus variant dominant in South Africa.
Read moreJOHANNESBURG, Feb 11 (Reuters) - The World Health Organization is briefing African countries on a recommendation by its SAGE panel that AstraZeneca's COVID-19 vaccine should be deployed widely, even in countries where the "South African" coronavi...
Read moreBy Pushkala AripakaLONDON, Feb 11 (Reuters) - AstraZeneca expects to produce more than 100 million doses of its COVID-19 vaccine - developed with Oxford University - this month, ramping up to more than 200 million a month by April, Chief Executive...
Read more* Vaccine one of best suited to African health systems* But trial showed lower efficacy vs variant in S.Africa* S.Africa could seek to swap AstraZeneca doses* AU disease body says to conduct own evaluations* WHO recommends using vaccine even where va...
Read more(Adds detail, context, Kenya)JOHANNESBURG, Feb 11 (Reuters) - The African Union's disease control body said on Thursday that it was not "walking away" from AstraZeneca's COVID-19 vaccine, after trial data showed it had greatly reduced efficacy aga...
Read more(Adds details)NAIROBI, Feb 11 (Reuters) - Kenya is going ahead with its plan to inoculate its citizens against COVID-19 using a vaccine developed by AstraZeneca, a senior health ministry official said on Thursday, dismissing concerns over its eff...
Read moreNAIROBI, Feb 11 (Reuters) - Kenya is going ahead with its plan to inoculate its citizens against COVID-19 using a vaccine developed by AstraZeneca, a senior ministry of health official said on Thursday, dismissing concerns over its efficacy."We a...
Read more
LONDON MARKET OPEN: FTSE Edges Up After Strong Annual Results
Read moreJOHANNESBURG, Feb 11 (Reuters) - The African Union's disease control body is in discussions with Johnson & Johnson for the supply of more COVID-19 vaccine doses, its director John Nkengasong said on Thursday.Nkengasong added that the body was not ...
Read more* British variant mutation is a worry - UK genetic chief* Some mutations may undermine vaccines - genetic chief* Vaccines so far effective, drug companies say* UK variant will sweep the world - UK genetic chief* Says: We'll be doing this a decade fro...
Read more
Last checked at